Scancell announced that dosing of patients has commenced in Cohort 4 of its Phase 2 clinical SCOPE study. This cohort will evaluate iSCIB1+ Immunobody® through intradermal administration and accelerated dosing in patients with advanced unresectable melanoma. As a reminder, cancer vaccine SCIB1/iSCIB1+ is being explored as a combination therapy in advanced skin cancer (which we estimate to be a more than £1bn market opportunity), where just 19% of individuals live beyond 5 years. The new intrader ....
